Statin Use and Candidemia Outcomes in Adults

What is it about?

In this multicenter study involving 326 hospitalized adults with candidemia, statin users had a lower early (5 d) case-fatality rate than non-users (4.5% vs. 17%; p=.031). After adjusting for confounders, appropriate empirical antifungal therapy, and prior statin use were independently associated with lower early case-fatality. However, there were no differences regarding appropriate empirical antifungal treatment. The overall and 14-day case-fatality rates were similar between groups. The study suggests that statins might have a beneficial effect on the outcomes of patients with candidemia, which deserves further evaluation in randomized trials. [Some of the content on this page has been created by AI]

Featured Image

Why is it important?

This research is important as it investigates the potential beneficial effect of statins on the outcomes of patients with candidemia. Understanding the impact of statins in this context could potentially lead to improved treatment strategies and patient outcomes. Key Takeaways: 1. Statin users had a lower early case-fatality rate than non-users. 2. APACHE II score and appropriate empirical antifungal treatment were independently associated with lower early case-fatality. 3. Statin use might have a beneficial effect on outcomes of patients with candidemia, but further evaluation in randomized trials is needed.